Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Prevention of Chronic Lung Disease in Preterm Infants
NCT00551642Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- May 2005
- Primary completion
- Mar 2008
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) comparing Inhaled Nitric Oxide with Placebo (2 arms). Primary endpoint: Survival Without Bronchopulmonary Dysplasia at 21 days. Started May 2005; status: completed.
02
Drugs
nitric oxide
03
Conditions
respiratory distress syndrome (RDS)bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT00551642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551642.